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Helicases as antiviral drug targets
Key Messages
1. We have demonstrated for the 
first time that the helicase of 
a ribonucleic acid virus, the 
SARS coronavirus (SARS-
CoV), is a valid target for drug 
development.
2. Using high throughput screen 
and chemical synthesis, several 
lead compounds targeting the 
SARS-CoV helicase have been 
identified. We have shown that 
these compounds can inhibit 
SARS-CoV helicase activity 
and viral growth in cell culture 
systems. These compounds can 
potentially be used to target 
other viruses.
Introduction
SARS is a serious type of pneumonia that was first recognised in late 2002 and 
shown to be caused by the SARS coronavirus (SARS-CoV).1,2 We have previously 
reported on the purification and characterisation of the SARS-CoV helicase.3 We 
have assessed a number of drugs for their ability to inhibit SARS-CoV helicase 
activities and viral growth.4,5
 In order to validate the drug target, we generated drug-resistant SARS-
CoV strains. Since a compound can inhibit SARS-CoV replication by either 
interfering directly with the helicase or with a cellular target, it is necessary 
to verify whether the drugs are indeed targeting the helicase. If virus mutants 
resistant to an inhibitory compound can be selected, it is likely that the target 
of the inhibitor is a viral process. Drug targets can be identified by defining the 
gene in which the mutation conferring the resistant phenotype has occurred. To 
determine the molecular target, we selected resistant viruses in the presence of 
increasing concentrations of a SARS-CoV inhibitor—bananin—identified in 
this study.5 We then identified the nature of the mutation that confers bananin-
resistance. In parallel, we expanded the screen for SARS-CoV helicase inhibitors 
and synthesised several bananin derivatives with SARS-CoV–inhibiting effects.
Methods and results
This study was conducted from June 2004 to May 2006.
Confirmation of helicase as valid drug target
The SARS-CoV were cultured with FRhK-4 in a 96-well plate in the presence 
of bananin. The released viruses in the culture medium were collected and 
used to infect a fresh batch of FRhK-4 cells. After three passages, selected 
SARS-CoV were cultured in the presence of increasing amounts of bananin. 
Several independently bananin-resistant strains were then isolated. Their 
growth in the presence of bananin were compared to that of the wild type of 
SARS-CoV to confirm their drug resistance. We then identified the nature 
of the mutation that conferred bananin-resistance. Briefly, viral ribonucleic 
acid (RNA) from resistant strains was prepared as described previously.3 The 
helicase genes were cloned as reverse transcription–polymerase chain reaction 
(PCR) products. Clones were verified using restriction enzyme digestion and 
subjected to sequencing analysis. Sequencing confirmed mutations in the 
SARS-CoV helicase. Back titration (Fig 1) and real-time PCR showed that in 
the presence of 50 or 100 µM of bananin, mutant clones exhibit 4 to 6 times 
higher resistance than the wild type virus.
 To investigate whether the helicase gene is responsible for drug resistance, we 
first sequenced the helicase genes of all drug-resistant strains, and found that they 
all contained a point mutation in the beginning of the helicase domain, causing 
Ser259, a potent phosphorylation site, to change into leucine.
 We established cell lines expressing either wild types or mutants. These 
cell lines were infected with wild-type SARS-CoV in the presence of different 
concentrations of bananin. The supernatants were collected and back titrated on 
fresh cells. Virus RNA was also extracted and real-time PCR was performed 
to monitor viral replication. Mutant helicase expression can rescue wild-type 
SARS-CoV replication in the presence of bananin, indicating that helicase is the 
authentic target for bananin in vivo (Fig 2).
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Screen for more SARS-CoV helicase inhibitors
We used a chemical library of 50 240 structurally diverse 
small molecule compounds in a cell-based assay to screen 
for small molecule compounds that curb the infectivity of 
the virus. In the primary screening using high concentrations 
of each compound, we identified 1003 compounds that 
protect cells from SARS-CoV–induced cell death. These 
compounds were re-tested and the concentration of selected 
compounds was lowered during a secondary screening. A 
total of 108 compounds retained consistent and significant 
protective effects against SARS-CoV–induced cell death. 
To identify compounds that inhibit the SARS-CoV helicase, 
we then screened the active compounds against the 
polynucleotide stimulated ATPase activity of SARS-CoV 
helicase. Seven compounds exhibited SARS-CoV helicase 
inhibitory activity.4
Synthesis of bismuth complexes against SARS-CoV
We have previously demonstrated that bismuth compounds 
can effectively inhibit SARS-CoV growth in cell culture. A 
series of bismuth complexes were designed and synthesised, 
including bismuth porphyrin complexes, bismuth 
macrocyclen complexes, bismuth 12-crown-4 complex, 
bismuth bipyridine complex, bismuth phenanthroline 
complex, Bi(NTA), Bi(EDTA) and Bi(AHA)3. The newly 
synthesised compounds were tested for their activities 
against SARS helicase. Among these complexes, we found 
that the two bismuth porphyrin complexes and red blood 
cell exhibited the best inhibition activity in the in-vitro 
experiments.
 In summary, we used reverse genetic methods to 
identify natural targets for the SARS-CoV inhibitor 
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Fig 1. Bananin-resistance of selected virus strains (SCV) 
SCV were cultured on FRhK-4 cells in the presence of 100 
µM bananin. After several passages, 11 resistant strains were 
picked from independent clones. Titration of several virus clones 
including B6, B14, B15, B15, and wild-type virus control (WT) 
were carried out on FRhK-4 cells in the presence of different 
concentration of BAN to verify drug resistance
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Fig 2. Expression of mutant helicase or M protein can rescue wild type selected virus strains (SCV) replication in the presence 
of BAN 
Wild-type FRhK-4 cells (WT) or FRhK-4 cells stably expressing wild type M (M), mutant M bearing Ala68/Val and Arg124/Trp (mM), 
wild-type helicase (Hel) or mutant helicase bearing Ser259/Leu (mHel) were infected with wild-type SCV in the presence of 0, 10, 
50 µM BAN. (a) Back titration or (b) Q real time–polymerase chain reaction (PCR) showed SCV can replicate in FRhK-4 cells with 
expression of mutant M or helicase in the presence of BAN. Virus titres (a) or helicase copies/β-actin (b) in absence of BAN were set as 
100%. Data in (b) were derived from three independent experiments
Huang et al
38      Hong Kong Med J Vol 14 No 4 Supplement 4 August 2008
bananin. We have found functional mutations in helicase 
proteins in bananin-resistant strains. The mutant protein 
expressed in cultured cells can rescue wild-type SARS-
CoV replication in the presence of bananin. In addition, 
we have identified 108 compounds that can inhibit SARS-
CoV growth, seven of which exhibited inhibitory activity 
against the SARS-CoV helicase.4 Furthermore, bismuth 
complexes with an IC
50 
 (median inhibition concentration, 
ie concentration that reduces the effect by 50%) lower 
than micromolar concentration and displaying extremely 
low toxicities towards normal cells have been synthesised. 
Further development, including testing in animal models, of 
the lead compounds developed in this study is worthwhile. 
These compounds also have the potential to be effective 
against other viruses.
Acknowledgements
This study was supported by the Research Fund for the 
Control of Infectious Diseases (RFCID: 01030182), Food 
and Health Bureau, Hong Kong SAR Government. We 
also thank all the research workers involved for their hard 
work.
References
1. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus 
associated with severe acute respiratory syndrome. N Engl J Med 
2003;348:1953-66.
2. Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of 
severe acute respiratory syndrome. Lancet 2003;361:1319-25.
3. Tanner JA, Watt RM, Chai YB, et al. The severe acute respiratory 
syndrome (SARS) coronavirus NTPase/helicase belongs to a distinct 
class of 5’ to 3’ viral helicases. J Biol Chem 2003;278:39578-82.
4. Kao RY, Tsui WH, Lee TS, et al. Identification of novel small-mol-
ecule inhibitors of severe acute respiratory syndrome-associated 
coronavirus by chemical genetics. Chem Biol 2004;11:1293-9.
5. Tanner JA, Zheng BJ, Zhou J, et al. The adamantane-derived ba-
nanins are potent inhibitors of the helicase activities and replication 
of SARS coronavirus. Chem Biol 2005;12:303-11.
